

FOR IMMEDIATE RELEASE

For more information:
Lora Quinn
(678) 778-8968
lquinn@nextpharmaceuticals.com

Next Pharmaceuticals Appoints Deanne Dolnick as Vice President

Former sales executive and 11-year veteran of the natural products industry will lead sales and operations

Salinas, CA – August 27, 2010 – Today Next Pharmaceuticals announced the appointment of Deanne Dolnick, a five-year sales executive with the company, to vice president. Dolnick, an 11-year veteran of the natural products industry, has held various leadership positions in sales, training and product management and has a master of science degree in dietetics from California State University, Northridge. In her new role, she will lead operations and sales for Next Pharmaceuticals.

During her tenure at Next, Dolnick most recently directed the process for getting the company up to cGMP regulations as required by the FDA, which included overseeing quality assurance, quality control, operations and personnel training. In her role as sales director, Dolnick drove significant increases in revenue and boosted sales significantly during the height of the economic recession from 2008-2009.

“Deanne has been instrumental in helping Next Pharmaceuticals evolve into a company that not only provides top quality health supplements that are sold across the world, but also conforms to the highest consumer and regulatory standards,” says Next Pharmaceuticals CEO Charles Kosmont. “Her expertise and dedication have contributed to the company’s growth and development, and I’m certain that she’ll accomplish even more in her new leadership role.”

About Next Pharmaceuticals:

Founded in 1997, Next Pharmaceuticals (Next) provides patented, science-based natural ingredients for healthy living products in the dietary supplement, food and beverage industries. Next has successfully developed six patented and proprietary plant extracts as well as Chromulin[®], a new, safer form of the essential trace mineral chromium. Next products help consumers cope with many of today’s most prevalent and chronic health issues, significantly expanding the choices for self-care products while providing consumer brands with powerful product differentiation. Next proprietary formulations include Relora[®] for stress, stress-related eating and weight management; Seditol[®] for improved, more restful sleep; Nexrutine[®] for inflammation due to over exertion and exercise; Citi-Z[®] for heart health; Flavoxine[®] for balanced cholesterol levels; and Citrofen[®] for joint mobility and comfort. For more information, visit www.nextpharmaceuticals.com

###